The purpose of this study is to assess the safety and efficacy of NK042 for treatment of malignant <a target="_blank" href="http://ascites/">ascites</a>.
Detailed Description
This is a phase 1 ,open-label , Single Arm,dose escalation study to evaluate the safety, tolerability, PK, PD and preliminary efficacy of NK042 in patients with treatment of malignant ascites caused by <a target="_blank" href="https://clin.larvol.com/trial-detail/NCT06415500">Gynecologic Can</a>cer.About 3–9 subjects are planned to be enrolled, Subjects will receive intraperitoneal infusion of NK042 once a week (D0、D7、D14)for 2 cor 2 cycles, with ycles, with 3 times during each cycle and a total of 6 infusions. The occurrence of DLTs will be observed from the first intraperitoneal infusion of NK042 to 28 days after infusion.

The purpose of this study is to assess the safety and efficacy of NK042 for treatment of malignant [**ascites**](http://ascites/).

**Detailed Description**

This is a phase 1 ,open-label , Single Arm,dose escalation study to evaluate the safety, tolerability, PK, PD and preliminary efficacy of NK042 in patients with treatment of malignant ascites caused by [**Gynecologic Can**](https://clin.larvol.com/trial-detail/NCT06415500)**cer**.About 3–9 subjects are planned to be enrolled, Subjects will receive intraperitoneal infusion of NK042 once a week (D0、D7、D14)for 2 cor 2 cycles, with ycles, with 3 times during each cycle and a total of 6 infusions. The occurrence of DLTs will be observed from the first intraperitoneal infusion of NK042 to 28 days after infusion.

Phase I Study of NK042 for Safety and Efficacy in Treating Malignant Ascites from Gynecologic Cancer